Dr Reddy’s Laboratories (DRL) announced its unaudited consolidated financial results for the quarter ended September 30, 2012 under International Financial Reporting Standards (IFRS). The consolidated revenues for Q2 FY13 at Rs 28.8 billion, recorded YoY growth of 27 per cent. Consolidated revenues for H1 FY13 at Rs 54.2 billion, recorded YoY growth of 28 per cent. Revenues from the global generics segment for Q2 FY13 at Rs 20.1 billion, recorded YoY growth of 25 per cent primarily driven by North America, India and other emerging markets.
Revenues from the PSAI segment for Q2 FY13 at Rs 7.9 billion, recorded YoY growth of 33 per cent.
Earnings before interest, taxes, depreciation, and amortization (EBITDA) for Q2 FY13 at Rs 7.7 billion, 27 per cent of revenues, recorded YoY growth of 47 per cent. EBITDA for H1 FY13 at Rs 12.7 billion, 23 per cent of revenues, recorded YoY growth of 35 per cent.
PAT for Q2 FY13 at Rs.4.1 billion, 14 per cent of revenues, recorded YoY growth of 32%. PAT for H1 FY13 at Rs.7.4 billion, 14% of revenues, recorded YoY growth of 30%.
During the quarter, the company launched 18 new generic products, filed 11 new product registrations and filed 10 DMFs globally.
EP News Bureau
- Advertisement -
